RVNC News and Press, Revance Therapeutics Inc. From 11/04/22

- Precise injection technique and comprehensive patient assessment can lead to optimized aesthetic outcomes when treating frown lines - Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial-stage biotechnology company focused on innovative aesthetic and therapeutic offerin...

Conference Call Scheduled for Tuesday, November 8, 2022 at 4:30 p.m. ET Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will release third quarter ...

Revance Therapeutics ( NASDAQ: RVNC ) has submitted a supplemental Biologics License Application (sBLA) to the US FDA for Daxxify (daxibotulinumtoxinA-lanm) to gain an indication for cervical dystonia. The ailment is a chronic condition in which the neck musc...

- sBLA filing based on the pivotal ASPEN Phase 3 program demonstrating DAXXIFY’s median duration of response of 24 weeks in the treatment of cervical dystonia - Anticipated PDUFA target action date in 2023 Revance Therapeutics, Inc. (Nasdaq: RVNC) a biotechnol...

Revance Therapeutics ( NASDAQ: RVNC ) has announced the appointment of David A. Hollander, M.D., M.B.A., as Chief Medical Officer to lead clinical development, data science, medical affairs, scientific innovation, pharmacovigilance and regulatory affairs. He was most ...

Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced the appointment of David A. Hollander, M.D., M.B.A., as Chief Medical Officer to lead clinical development, data science, medica...

-- Subgroup analysis from SAKURA 3 demonstrating the safety and efficacy of DAXXIFY™ in black patients -- -- High level of satisfaction in DAXXIFY™ patients who achieved the elimination of glabellar lines, consistent across subgroups -- Revance Ther...

U.S. stock futures were slightly lower on Thursday morning following a big decline in the major averages as traders weighed another large rate hike from the Federal Reserve. Futures for the Dow Jones Industrials faded 32 points, or 0.1%, early Thursday to 30,250. Futures for the...

Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will participate in the Guggenheim Nantucket Therapeutics Conference, taking place September 27 – 29, in...

- Glabellar injection of DAXXIFY™ demonstrated a positive effect on eyebrow position - - DAXXIFY™ demonstrated a high response rate and duration of effect ≥24 weeks across all age and race subgroups - Revance Therapeutics, Inc. (Nasdaq: RVNC), a ...